As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Continuously developing novel drugs is one of the most important things a pharmaceutical company can do to remain successful ...

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...

The Cancer Equals campaign Greene is supporting was launched by international bio-pharmaceutical company Bristol Myers Squibb ...

BMS said it will launch Cobenfy within the next ... glycine transporter 1 inhibitor iclepertin in phase 3, Newron Pharma's sodium channel blocker evenamide, which had encouraging phase 2/3 data ...

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...